Michael Yee
Stock Analyst at Jefferies
(3.49)
# 819
Out of 4,760 analysts
81
Total ratings
43.64%
Success rate
6.88%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.97 | +208.20% | 5 | Mar 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $3 | $3.92 | -23.47% | 3 | Jan 30, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $3.65 | +447.95% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $143.66 | +25.30% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $488.34 | +12.63% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $318.89 | +19.16% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $15.04 | +199.20% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $33.76 | +62.91% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $9.19 | +280.85% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $11.06 | +261.66% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $526.64 | -26.90% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.29 | +336.68% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $1.50 | +100.00% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $26.42 | +13.57% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $0.47 | +112.59% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $34.50 | -42.03% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $10.51 | +613.61% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.43 | +1,997.90% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $28.42 | +128.71% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.41 | +10,793.25% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.55 | +1,835.48% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $13.75 | +118.18% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $10.81 | +1,010.08% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $21.66 | +246.26% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $13.60 | +120.59% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $10.82 | +611.65% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $114.43 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.97
Upside: +208.20%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $3
Current: $3.92
Upside: -23.47%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $3.65
Upside: +447.95%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $143.66
Upside: +25.30%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $488.34
Upside: +12.63%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $318.89
Upside: +19.16%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $15.04
Upside: +199.20%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $33.76
Upside: +62.91%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $9.19
Upside: +280.85%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $11.06
Upside: +261.66%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $526.64
Upside: -26.90%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.29
Upside: +336.68%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.50
Upside: +100.00%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $26.42
Upside: +13.57%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.47
Upside: +112.59%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $34.50
Upside: -42.03%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $10.51
Upside: +613.61%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $1.43
Upside: +1,997.90%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $28.42
Upside: +128.71%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.41
Upside: +10,793.25%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.55
Upside: +1,835.48%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $13.75
Upside: +118.18%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $10.81
Upside: +1,010.08%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $21.66
Upside: +246.26%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $13.60
Upside: +120.59%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $10.82
Upside: +611.65%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $114.43
Upside: -